Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page update adds a Gastric cancer tag and a new link to the Genetic and Rare Diseases Information Center in the Resources section, and it updates the revision from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check19 days agoChange DetectedFooter now displays Revision: v3.4.1, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedIntroduced a glossary toggle and added QC-related metadata (Last Update Submitted that Met QC Criteria and Last Update Posted) with revision updated to v3.4.0. Removed the previous QC label (Last Update Submitted that met QC Criteria), the estimated Last Update Posted label, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was published, replacing the previous v3.3.3. No visible changes to the study details or page layout are indicated by the screenshot.SummaryDifference0.0%

- Check63 days agoChange DetectedNew location sections were added for California, Illinois, Massachusetts, New York, and Nouvelle-Aquitaine and old location sections were removed; the revision updated from v3.3.2 to v3.3.3.SummaryDifference0.4%

- Check91 days agoChange DetectedRevision updated to v3.3.2 (replacing v3.2.0) on the Study Details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.